O. Bolte

Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.

A. Ganser, P. Schöffski, H. Lentzen, 2005, European journal of cancer.

AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)

R. Motzer, M. Michaelson, G. Wilding, 2005 .

Preparation and evaluation of 211At labelled antineoplastic antibodies.

M. Hofmann, W. Knapp, G. Meyer, 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia

A. Ganser, M. Hofmann, B. Hertenstein, 2008, International journal of hematology.

Acral Necrosis after Inadequate Excessive Administration of Bleomycin in a Testicular Cancer Patient

A. Ganser, V. Grünwald, P. Schöffski, 2004, Oncology Research and Treatment.

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

D. Lacombe, M. Campone, H. Zwierzina, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

R. Motzer, M. Michaelson, G. Wilding, 2007, The Lancet. Oncology.

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

A. Ganser, J. Wanders, P. Schöffski, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.